Nanogen Issued European Patent for Key Nanomanufacturing and Nanotechnology Methods

Apr 27, 2005, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Nanogen, Inc.
 (Nasdaq:   NGEN), developer of advanced diagnostic products, announced today
 that it has been issued European Patent No. 0943158B1, "Affinity Based
 Self-Assembly Systems and Devices for Photonic and Electronic Applications,"
 by the European Patent Office.  This patent is similar to U.S. Patent
 6,652,808, the parent of a series of patent applications that significantly
 broaden Nanogen's proprietary position in the nanotechnology and
 nanomanufacturing areas.  The U.S. patent was issued in December 2003.
     The new nanotechnology patent relates to a nanofabrication technology that
 combines an electric field assisted manufacturing platform and programmable
 self-assembling nanostructures (for example, DNA building blocks) for the
 fabrication of a wide range of unique higher-order nano and microscale
 devices, structures and materials.  The nanofabrication platform and process
 would be used for: producing nanoscale electronic and photonic devices and
 structures; assembly of nanostructures and submicron components onto silicon
 wafers and other materials; integration of nanostructures within preformed
 microelectronic and optoelectronic structures; production of nanoparticles
 (for example, photonic crystals, nanospheres and quantum dots); and
 fabrication of selectively addressable DNA nanoarray substrates and materials.
     The patent represents a unique nanofabrication technology that combines
 the best aspects of top-down microfabrication processes with bottom-up
 biological self-assembly processes for producing novel nanodevices and
 nanostructures.  The European patent is jointly owned by Nanotronics, Inc., a
 wholly owned subsidiary of Nanogen, and the Regents of the University of
 California.  Nanogen has exclusively licensed the interests of the University
 of California where there is joint inventorship.
     About Nanogen, Inc.
     Nanogen's advanced diagnostics provide physicians and patients worldwide
 with sophisticated information to predict, diagnose and treat disease.
 Research and clinical reference labs use the highly accurate and reliable
 NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
 and broad suite of analyte specific reagents to develop diagnostic tests for
 variety of diseases.  Nanogen also offers a broad portfolio of patented
 nucleic acids chemistries and molecular tools that accelerate genomic analysis
 and are compatible with many systems.  The SynX subsidiary offers a line of
 point-of-care diagnostic tests and is building expertise in cardiac related
 health conditions.  Nanogen's ten years of pioneering research involving
 nanotechnology may also have future applications in medical diagnostics,
 biowarfare and other industries.  For additional information please visit
 Nanogen's website at
     Nanogen Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.